Fengxun Biotechnology has recently made public the successful conclusion of its Pre-A round financing, amassing hundreds of millions of yuan with contributions from both new and returning investors. The bulk of the capital raised will be earmarked for propelling the non-clinical development and regulatory approval processes of its in vivo CAR-T pipelines, which are aimed at treating hematologic malignancies and solid tumors. Additionally, the funds will be utilized to bolster a comprehensive, closed-loop technology platform for in vivo CAR-T, which is powered by generative AI. Established in May 2025, Fengxun Biotechnology has, since its inception, amassed a cumulative funding total nearing 200 million yuan. The company's core leadership team boasts end-to-end expertise in the development of CAR-T and gene therapy products. At present, the global CAR-T cell therapy market is witnessing swift expansion. In vivo CAR-T technology is widely regarded as a pivotal avenue for enhancing the accessibility of cell therapies, as it mitigates the high costs and lengthy timelines associated with conventional ex vivo CAR-T methods. This has spurred investment from capital sources worldwide, with numerous companies, both domestic and international, advancing their pipelines to clinical stages. Fengxun Biotechnology has constructed an integrated, full-process, closed-loop platform for in vivo CAR-T, merging "AI-driven generation with swift wet-lab validation." This platform leverages generative AI across various crucial R&D phases and has achieved significant advancements in the design and validation of novel AI-generated membrane fusion proteins. Its next-generation in vivo CAR-T candidate products have successfully cleared pivotal efficacy and safety validations in clinical trials. Simultaneously, Fengxun Biotechnology has fostered a positive feedback loop between AI and laboratory operations through its proprietary AI platform. By utilizing lentiviral vectors as the foundation for delivery and integrating generative AI, the company has cultivated distinctive competitive advantages. Currently, Fengxun Biotechnology is advancing multiple clinical pipelines related to tumor treatment in tandem, achieving several key technical milestones in the development of multi-target and armored products. It is actively engaged in non-clinical research and preparing IND regulatory submissions for these pipelines. Furthermore, the company has conducted comprehensive research in areas such as lentiviral vector production, establishing a robust groundwork for subsequent clinical pharmaceutical support and process scaling.